New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on February 23, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Timothy Schmid, Executive Vice President and Worldwide Chair of MedTech at Johnson & Johnson, has sold 1,322 shares of Johnson & Johnson stock in a transaction valued at $324,762. This insider sale highlights a notable move by a key member of the company’s senior leadership team, drawing attention to recent activity in Johnson & Johnson’s executive stock holdings.
Recent Updates on JNJ stock
Johnson & Johnson shares have continued their strong uptrend, with analysts maintaining a moderately bullish stance and seeing further upside despite sizeable gains over the past year. Recent price‑target increases are mainly driven by confidence in a robust new product cycle in immunology and oncology, expectations of earnings beats, and the view that JNJ still trades at a discount to the broader market.
Analysts also cite sector‑wide tailwinds, including improved sentiment toward large biopharma after policy overhangs eased and capital rotated into the group. Additional support comes from company events such as Therapeutics Doctor Days, which led to higher forecasts for key drugs and reinforced the belief that new launches can offset loss‑of‑exclusivity pressures and sustain mid‑single‑digit revenue and double‑digit EPS growth through 2030.
Spark’s Take on JNJ Stock
According to Spark, TipRanks’ AI Analyst, JNJ is a Outperform.
The score is driven primarily by strong, durable cash generation and solid operating performance, reinforced by constructive 2026 guidance and portfolio/pipeline momentum. The rating is tempered by stretched technical conditions, moderate-to-premium valuation, and ongoing headwinds (tariffs, litigation/one-time charges, and residual biosimilar/competitive pressures).
To see Spark’s full report on JNJ stock, click here.
More about Johnson & Johnson
YTD Price Performance: 19.31%
Average Trading Volume: 8,965,059
Technical Sentiment Signal: Buy
Current Market Cap: $590.4B